University of Massachusetts Medical School

Sorting 1 by

Accepting patients

HMPL-306

A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies With Isocitrate Dehydrogenase (IDH) Mutations
Learn more
  • IDH1 Inhibitor
  • MIDH2 Inhibitor
  • Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials